Sugar therapy trial targets rare genetic disease
NCT ID NCT05402332
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 27 times
Summary
This study tests a sugar called D-galactose (AVTX-801) in 8 adults with PGM1-CDG, a rare inherited disorder that affects how the body makes proteins. Participants must already be taking D-galactose. The trial aims to see if the treatment reduces episodes of low blood sugar, liver stress, or blood clotting problems. It is a placebo-controlled crossover study, meaning each person will receive both the drug and a placebo at different times.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PGM1-CDG - PHOSPHOGLUCOMUTASE 1-RELATED CONGENITAL DISORDER OF GLYCOSYLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.